What are ASCO recommendations for third-line therapy of stage IV non–small cell lung cancer (NSCLC)?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

Recommendations for third-line therapy include the following:

  • For patients with BRAF mutations whose second-line therapy included immunotherapy, clinicians may offer dabrafenib alone or in combination with trametinib
  • For patients with non-SCC, negative or unknown tumor EGFR-sensitizing mutation, or ALK or ROS1 gene rearrangement status and PS 0-1 (or possibly PS 2), who received chemotherapy with or without bevacizumab and immune checkpoint therapy, clinicians should offer single-agent pemetrexed or docetaxel

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!